EGFR and non-small cell lung carcinoma: About 10% of EGFR wild-type patients respond to TKI, but the benefit is modest with unknown mechanisms of sensitivity.[18] It is noteworthy that there is little rationale for the investigation of EGFR-TKI therapy in EGFR wild-type NSCLC.